Table 3 Partial end-point components of the phenotypic prototypes from the clustering of the acetaminophen-treated samples.
| Â | Cluster | ||
|---|---|---|---|
Features | 1 | 2 | 3 |
Cong_Sinusoid | Moderate | None | Minimal |
Necr_Cent | Moderate | None | Mild |
Infl_Cent | None | None | Minimal/Mild* |
Hypert_Hepa | Minimal | None | None |
Regen_Hepa | None | None | Minimal |
Dege_Hepa* | None | None | Minimal |
ALB (g/dL) | 5.16 | 5.03 | 4.78 |
ALP (IU/L) | 413.22 | 323.43 | 368.78 |
ALT (IU/L) | 9649.40 | 118.48 | 1676.10 |
AST (IU/L) | 20304.00 | 171.80 | 2820.20 |
Creat (mg/dL) | 0.70 | 0.70 | 0.70 |
BUN (mg/dL) | 23.56 | 15.56 | 18.11 |
CHOLE (mg/dL) | 59.78 | 86.54 | 85.44 |
TBA (umol/L) | 61.67 | 7.61 | 43.56 |
SDH (IU/L) | 2.89 | 32.41 | 398.89 |
TP (g/dL) | 7.53 | 7.52 | 7.19 |
* Observed in the left medial lobe | Â | Â | Â |